Mixture-Design Optimization of an Intranasal Self-Nanoemulsifying Drug Delivery System Co-Loaded with Olmesartan Medoxomil and Apigenin: Composition Modeling and Ex Vivo Nasal Permeation

Background/Objectives: Ischemic brain injury involves parallel oxidative, inflammatory, and vascular cascades. Olmesartan medoxomil and apigenin act on complementary arms and can serve this purpose. This study developed a self-nanoemulsifying drug delivery system (SNEDDS) co-loaded with both agents for intranasal use. Constrained mixture design was used to determine its actual composition. Methods: Oil and cosolvent were selected by saturation solubility and surfactant by emulsification transmittance. The proportions of Kolliphor EL (40–70% w/w), poly(ethylene glycol) 400 (5–30% w/w), and Imwitor 308 (20–40% w/w) were treated as mixture variables and each drug’s solubility as the response. Desirability analysis identified the optimum composition, which was experimentally verified. After that, it was compared with a drug suspension for permeation across excised goat nasal mucosa in Franz diffusion cells. Results: Apigenin solubility followed a linear mixture model and olmesartan medoxomil a quadratic model. The optimum composition (52.33% Kolliphor EL, 27.67% poly(ethylene glycol) 400, 20.00% Imwitor 308) gave observed solubilities of 11.82 and 6.91 mg/g, within the 95% prediction intervals. Steady-state flux rose from 0.85 ± 0.68 to 8.46 ± 2.51 µg/cm2/h for olmesartan medoxomil and from 0.18 ± 0.17 to 10.06 ± 3.63 µg/cm2/h for apigenin. Conclusions: A constrained mixture design identified a SNEDDS composition that accommodated both drugs and markedly increased their transport across excised nasal mucosa relative to a suspension. These findings establish a formulation basis for the intranasal administration of this drug combination.

Authors

Institutions

Publication Details

Journal
Pharmaceutics
Published
2026-11-18
DOI
https://doi.org/10.3390/pharmaceutics18111487
Primary Topic
Advanced Drug Delivery Systems
Type
article
Field-Weighted Citation Impact
0.00

Funders

Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
article

Mixture-Design Optimization of an Intranasal Self-Nanoemulsifying Drug Delivery System Co-Loaded with Olmesartan Medoxomil and Apigenin: Composition Modeling and Ex Vivo Nasal Permeation

Mohamed M. Badran, Ehab Mostafa Elzayat, Abdelrahman Y. Sherif, Mohammad A. Altamimi et al.
1 links
Pharmaceutics
Advanced Drug Delivery Systems
article

Mixture-Design Optimization of an Intranasal Self-Nanoemulsifying Drug Delivery System Co-Loaded with Olmesartan Medoxomil and Apigenin: Composition Modeling and Ex Vivo Nasal Permeation

Mohamed M. Badran, Ehab Mostafa Elzayat, Abdelrahman Y. Sherif, Mohammad A. Altamimi, Sultan Almutairy
article en

Abstract

Background/Objectives: Ischemic brain injury involves parallel oxidative, inflammatory, and vascular cascades. Olmesartan medoxomil and apigenin act on complementary arms and can serve this purpose. This study developed a self-nanoemulsifying drug delivery system (SNEDDS) co-loaded with both agents for intranasal use. Constrained mixture design was used to determine its actual composition. Methods: Oil and cosolvent were selected by saturation solubility and surfactant by emulsification transmittance. The proportions of Kolliphor EL (40–70% w/w), poly(ethylene glycol) 400 (5–30% w/w), and Imwitor 308 (20–40% w/w) were treated as mixture variables and each drug’s solubility as the response. Desirability analysis identified the optimum composition, which was experimentally verified. After that, it was compared with a drug suspension for permeation across excised goat nasal mucosa in Franz diffusion cells. Results: Apigenin solubility followed a linear mixture model and olmesartan medoxomil a quadratic model. The optimum composition (52.33% Kolliphor EL, 27.67% poly(ethylene glycol) 400, 20.00% Imwitor 308) gave observed solubilities of 11.82 and 6.91 mg/g, within the 95% prediction intervals. Steady-state flux rose from 0.85 ± 0.68 to 8.46 ± 2.51 µg/cm2/h for olmesartan medoxomil and from 0.18 ± 0.17 to 10.06 ± 3.63 µg/cm2/h for apigenin. Conclusions: A constrained mixture design identified a SNEDDS composition that accommodated both drugs and markedly increased their transport across excised nasal mucosa relative to a suspension. These findings establish a formulation basis for the intranasal administration of this drug combination.

PharmaceuticsVol. 18(11)
King Saud University (SA)
King Saud University
Good health and well-being
Advanced Drug Delivery Systems
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon